EGFR and non-small cell lung carcinoma: Consistently, osimertinib as well as other EGFR-TKIs decreased the levels of Topo IIα in EGFRm NSCLC cells, and this was accompanied by increased DNA damage; these effects were lost in osimertinib-resistant cell lines that possessed elevated basal levels of Topo IIα.